Business Wire

KOLMAR-BNH

22.4.2024 05:00:33 CEST | Business Wire | Press release

Share
Hemohim, a Functional Food to Boost Immune System, Sparks Global Sensation

Hemohim is garnering remarkable popularity in the global market as Korea's one of the leading functional foods.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418277251/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kolmar BNH Sejong Factory (Photo: Kolmar BNH)

Hemohim is developed through an eight-year collaboration between Kolmar BNH (KOSDAQ: 200130) and the Korea Atomic Energy Research Institute, with an investment of KRW 5 billion. It was extracted from raw materials of angelica gigas, cnidium officinale, and paeonia japonica, which have been traditionally used in herbal medicine. Kolmar BNH performed tests on humans to confirm the safety and efficacy of its main ingredient, ‘HemoHIM Extract complex of Angelica gigas, etc.’, and was recognized by the Ministry of Food and Drug Safety of Korea in 2006 for its immune-boosting properties.

Distributed by Atomy, a customer of Kolmar BNH, Hemohim has sold over KRW 2 trillion worth of products in just 17 years since its launch, making it the nation’s best-selling individually approved health functional food. With strong demand from many countries like Australia, the US, and Thailand, Hemohim has expanded its global presence to over 20 countries.

Following a rigorous review process, Hemohim received approval from the Korean Ministry of Food and Drug Safety as the nation’s first individually approved health supplement product designed to enhance immune function.

Ranking the second-highest exported product after red ginseng in Korea, Hemohim is the leading individually approved health functional food ingredient. Kolmar BNH, propelled by Hemohim's success, was honored with the '200 Million Dollar Export Tower' at the 2021 'Trade Day' ceremony hosted by the Korea International Trade Association.

Kolmar BNH is making R&D efforts to sharpen its material competitiveness, as evidenced by the 'Hemohim Sustaining Technology Development Project.' After six years of endeavors, it obtained a fatigue recovery function last year, solidifying Hemohim's status as a dual-functional food with immune enhancement and fatigue recovery.

To further reach the European market, Kolmar BNH has developed HemohimG, tailored to suit European preferences in tastes and aroma. HemohimG is a product made for exports that follow the food regulations of each country. It is now poised for export to the UK and Turkey.

A Kolmar BNH official stated, "Hemohim represents Korea's top health functional food, backed by research capabilities and manufacturing prowess. After its success in Korea over the past 16 years, Hemohim is ready to leave its footprint on the global market."

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418277251/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 20281 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 07:30:00 CEST | Press release

Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements:Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio

OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 07:00:00 CEST | Press release

New portfolio combines high-performance cell culture media, molecule-specific CQA optimization, and integrated CDMO capabilities to help biosimilar developers accelerate the path to analytical similarity and improve process economics. OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of

H2SITE Secures €3.4 Million (NOK 39.1 million) in Enova Funding to Scale Onboard Ammonia-To-Power for Commercial Maritime Applications22.9.2026 06:00:00 CEST | Press release

The 700 kW system builds on H2SITE’s previous maritime deployments and is designed as a modular, replicable solution for auxiliary power onboard vessels H2SITE has secured €3.4 million (NOK 39.1 million) in funding from Enova for HydraNord Power, a project that will develop and validate a commercial-scale onboard ammonia-to-power system for the maritime sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921324898/en/ Enova is one of the Norwegian government's primary instruments for accelerating the country's climate and energy transition. Its primary responsibility is to manage the Climate and Energy Fund on behalf of the Norwegian government. For H2SITE, Enova’s support is a major milestone in the commercialisation of its onboard ammonia cracking technology, enabling the company to scale from proven maritime demonstrations to replicable commercial solutions for the global shipping industry. Led by H2SITE, HydraNord

EcoOnline Recognised as a Leader in Verdantix Green Quadrant: EHS Software 2026 for Third Time21.9.2026 18:43:00 CEST | Press release

EcoOnline achieved highest score for Safety Management and ranked among the top three vendors for Chemicals Management, Training and Contractor Safety with Lone Worker Protection a key differentiator. EcoOnline, the global provider of software that transforms how organisations protect people and the planet, has been recognised for the third consecutive time as a Leader in the independent Verdantix Green Quadrant: EHS Software 2026 report, with market-leading strength in Safety Management. The assessment evaluated leading vendors of environmental, health and safety software vendors across a range of capabilities and customer buying signals. Verdantix recognised EcoOnline’s strength in the areas organisations rely on to protect workers every day: Safety Management, Chemicals Management, AI-enabled Training and Contractor Safety. It reflects the changing needs of EHS buyers, who are increasingly looking for integrated platforms that connect everyday safety with broader operational risk an

rhode Announces the Return of Limited Edition Favorites and New Exclusives at Sephora Across Europe and the U.K.21.9.2026 15:00:00 CEST | Press release

rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), has announced that two community-favorite Peptide Lip Tints and a new Sephora-exclusive bag will launch at Sephora across Europe and the U.K. to celebrate the brand’s launch into Sephora in Europe on September 30, 2026. These items will join the brand’s assortment of high-performance skincare and hybrid makeup. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921199856/en/ rhode announces the return of limited edition favorites and new exclusives at Sephora across Europe and the U.K. To mark the occasion with Sephora across Europe and the U.K., rhode is offering early access to purchase fan-favorite, previously limited edition Peptide Lip Tint in Pretzel at Sephora in Europe and the U.K. on the brand’s launch date September 30, before the product joins rhode’s permanent assortment globally on rhodeskin.com on October 1 and at all r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye